Abstract
Purpose of Review
Cancer and cardiovascular disease are among the leading causes of morbidity and mortality in the USA. Cancer and cardiovascular disease have inflammatory underpinnings that have been associated with both the development and progression of these disease states.
Recent Findings
Inflammatory signaling has been found to be a critical event in both cardiovascular disease and cancer formation and progression. Further, many chemotherapeutic agents potentiate inflammation exacerbating existing cardiovascular disease or leading to its presence. The exact mechanisms of these interactions remain poorly understood.
Summary
The proinflammatory milieu observed in both cancer and cardiovascular disease likely plays an important role in the development and potentiation of both conditions. Further evaluation of this relationship will be critical in the development of new diagnostic and therapeutic modalities.
Similar content being viewed by others
Data Availability
N/A.
Code Availability
N/A.
References
Johnson CB, Davis MK, Law A, Sulpher J. Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients. Can J Cardiol. 2016;32:900–7.
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.
Kamp DW, Shacter E, Weitzman SA. Chronic inflammation and cancer: the role of the mitochondria. Oncology (Williston Park). 2011;25(400-10):13.
Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83:456S–60S.
Masoudkabir F, Sarrafzadegan N, Gotay C, et al. Cardiovascular disease and cancer: evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis. 2017;263:343–51.
Kundu JK, Surh YJ. Emerging avenues linking inflammation and cancer. Free Radic Biol Med. 2012;52:2013–37.
de Kleijn D, Pasterkamp G. Toll-like receptors in cardiovascular diseases. Cardiovasc Res. 2003;60:58–67.
Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271–89.
Zöller B, Ji J, Sundquist J, Sundquist K. Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden. Eur J Cancer. 2012;48:121–8.
Whitlock MC, Yeboah J, Burke GL, Chen H, Klepin HD, Hundley WG. Cancer and its association with the development of coronary artery calcification: an assessment from the Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc. 2015:4.
Bharadwaj A, Potts J, Mohamed MO, et al. Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA. Eur Heart J. 2020;41:2183–93.
Han XJ, Li JQ, Khannanova Z, Li Y. Optimal management of coronary artery disease in cancer patients. Chronic Dis Transl Med. 2019;5:221–33.
Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133:1104–14.
Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96:939–49.
Picon-Ruiz M, Pan C, Drews-Elger K, et al. Interactions between adipocytes and breast cancer cells stimulate cytokine production and drive Src/Sox2/miR-302b-mediated malignant progression. Cancer Res. 2016;76:491–504.
Berstad P, Coates RJ, Bernstein L, et al. A case-control study of body mass index and breast cancer risk in white and African-American women. Cancer Epidemiol Biomarkers Prev. 2010;19:1532–44.
Cespedes Feliciano EM, Chen WY, Bradshaw PT, et al. Adipose tissue distribution and cardiovascular disease risk among breast cancer survivors. J Clin Oncol. 2019;37:2528–36.
Rodrigues Dos Santos C, Fonseca I, Dias S, Mendes de Almeida JC. Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression. BMC Cancer. 2014;14:132.
Morganti M, Carpi A, Nicolini A, et al. Atherosclerosis and cancer: common pathways on the vascular endothelium. Biomed Pharmacother. 2002;56:317–24.
Ross JS, Stagliano NE, Donovan MJ, Breitbart RE, Ginsburg GS. Atherosclerosis and cancer: common molecular pathways of disease development and progression. Ann N Y Acad Sci. 2001;947:271–92.
Navi BB, Reiner AS, Kamel H, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017;70:926–38.
Milazzo V, Cosentino N, Campodonico J, et al. Characteristics, management, and outcomes of acute coronary syndrome patients with cancer. J Clin Med. 2020:9.
Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol. 2002;3:27–34.
Munoz E, Iliescu G, Vejpongsa P, et al. Takotsubo stress cardiomyopathy: "good news" in cancer patients? J Am Coll Cardiol. 2016;68:1143–4.
Rinde LB, Småbrekke B, Hald EM, et al. Myocardial infarction and future risk of cancer in the general population-the Tromsø Study. Eur J Epidemiol. 2017;32:193–201.
Naschitz JE, Yeshurun D, Abrahamson J, et al. Ischemic heart disease precipitated by occult cancer. Cancer. 1992;69:2712–20.
Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol. 2012;35:443–50.
Iannaccone M, D'Ascenzo F, Vadalà P, et al. Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy. Eur Heart J Acute Cardiovasc Care. 2018;7:631–8.
Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64:e139–228.
Picano E, Mathias W, Pingitore A, Bigi R, Previtali M. Safety and tolerability of dobutamine-atropine stress echocardiography: a prospective, multicentre study. Echo Dobutamine International Cooperative Study Group. Lancet. 1994;344:1190–2.
Min JK, Shaw LJ, Devereux RB, et al. Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. J Am Coll Cardiol. 2007;50:1161–70.
Chrapko BE, Chrapko M, Nocuń A, Stefaniak B, Zubilewicz T, Drop A. Role of 18F-FDG PET/CT in the diagnosis of inflammatory and infectious vascular disease. Nucl Med Rev Central Eastern Eur. 2016;19:28–36.
Belhocine T, Blockmans D, Hustinx R, Vandevivere J, Mortelmans L. Imaging of large vessel vasculitis with 18FDG PET: illusion or reality? A critical review of the literature data. Eur J Nucl Med Mol Imaging. 2003;30:1305–13.
Blockmans D. The use of (18F)fluoro-deoxyglucose positron emission tomography in the assessment of large vessel vasculitis. Clin Exp Rheumatol. 2003;21:S15–22.
Lim E, Li Choy L, Flaks L, et al. Detected troponin elevation is associated with high early mortality after lung resection for cancer. J Cardiothorac Surg. 2006;1:37.
Danese E, Montagnana M, Giudici S, et al. Highly-sensitive troponin I is increased in patients with gynecological cancers. Clin Biochem. 2013;46:1135–8.
Pavo N, Raderer M, Hülsmann M, et al. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart. 2015;101:1874–80.
Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474–81.
Cardinale D, Salvatici M, Sandri MT. Role of biomarkers in cardioncology. Clin Chem Lab Med. 2011;49:1937–48.
Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231–47.
Souza VB, Silva EN, Ribeiro ML, WeA M. Hypertension in patients with cancer. Arq Bras Cardiol. 2015;104:246–52.
Małyszko J, Małyszko M, Kozlowski L, Kozlowska K. Hypertension in malignancy-an underappreciated problem. Oncotarget. 2018;9:20855–71.
Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J. 2008;14:288–301.
Du W, Zhang L, Brett-Morris A, et al. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. Nat Commun. 2017;8:1769.
Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49:1603–16.
Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 1. J Am Coll Cardiol. 2017;70:2536–51.
Martins WA, Rosa MLG, Matos RC, et al. Trends in mortality rates from cardiovascular disease and cancer between 2000 and 2015 in the most populous capital cities of the five regions of Brazil. Arq Bras Cardiol. 2020;114:199–206.
Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol. 2007;157:545–59.
Fiotti N, Altamura N, Cappelli C, Schillan M, Guarnieri G, Giansante C. Long term prognosis in patients with peripheral arterial disease treated with antiplatelet agents. Eur J Vasc Endovasc Surg. 2003;26:374–80.
Kaschwich M, Peters F, Hischke S, et al. Long-term incidence of cancer after index treatment for symptomatic peripheral arterial disease - a health insurance claims data analysis. Vasa. 2020;49:493–9.
Wiles B, Comito M, Labropoulos N, Santore LA, Bilfinger T. High prevalence of abdominal aortic aneurysms in patients with lung cancer. J Vasc Surg. 2021;73:850–5.
Blochle R, Lall P, Cherr GS, et al. Management of patients with concomitant lung cancer and abdominal aortic aneurysm. Am J Surg. 2008;196:697–702.
Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5:378–89.
Wang JC, Chien WC, Chung CH, et al. Increased risk of malignancy in patients with an aortic aneurysm: a nationwide population-based retrospective study. Oncotarget. 2018;9:2829–37.
Hiranuma K, Kusunoki S, Fujino K, Hirayama T, Ota T, Terao Y. Drug-induced aortitis in a patient with ovarian cancer treated with bevacizumab combination therapy. Taiwanese J Obst Gynecol. 2018;57:750–2.
Eyre TA, Gooding S, Patel I, Moore N, Hatton C, Collins GP. Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect. Int J Hematol. 2014;99:798–800.
Taimen K, Heino S, Kohonen I, et al. Granulocyte colony-stimulating factor- and chemotherapy-induced large-vessel vasculitis: six patient cases and a systematic literature review. Rheumatol Adv Prac. 2020:4.
Quack H, Erpenbeck L, Wolff HA, et al. Oxaliplatin-induced leukocytoclastic vasculitis under adjuvant chemotherapy for colorectal cancer: two cases of a rare adverse event. Case Rep Oncol. 2013;6:609–15.
Dawood S, Leyland-Jones B. Pharmacology and pharmacogenetics of chemotherapeutic agents. Cancer Invest. 2009;27:482–8.
Cameron AC, Touyz RM, Lang NN. Vascular complications of cancer chemotherapy. Can J Cardiol. 2016;32:852–62.
Soultati A, Mountzios G, Avgerinou C, et al. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev. 2012;38:473–83.
Berger NA. Alkylating agents. Cancer Chemother Biol Response Modif. 1996;16:28–38.
Kufe DW, Holland JF, Frei E. American Cancer Society. Cancer medicine 6. 6th ed. Hamilton, Ont Lewiston, NY: BC Decker; 2003.
Sales ARK, Negrao MV, Testa L, et al. Chemotherapy acutely impairs neurovascular and hemodynamic responses in women with breast cancer. Am J Physiol Heart Circ Physiol. 2019;317:H1–H12.
McGraw MD, Kim SY, White CW, Veress LA. Acute cytotoxicity and increased vascular endothelial growth factor after in vitro nitrogen mustard vapor exposure. Ann N Y Acad Sci. 2020;1479:223–33.
Ranchoux B, Gunther S, Quarck R, et al. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol. 2015;185:356–71.
Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. J Clin Oncol. 1986;4:1405–17.
Joseph D, Dubashi B, Karthikeyan B, Jain A. Arterial occlusion precipitated by cisplatinbased chemotherapy. Curr Oncol. 2010;17:71–2.
Kirwan CC, McCollum CN, McDowell G, Byrne GJ. Investigation of proposed mechanisms of chemotherapy-induced venous thromboembolism: endothelial cell activation and procoagulant release due to apoptosis. Clin Appl Thromb Hemost. 2015;21:420–7.
Coward J, Maisey N, Cunningham D. The effects of capecitabine in Raynaud's disease: a case report. Ann Oncol. 2005;16:835–6.
Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res. 1993;53:3028–33.
Sara JD, Kaur J, Khodadadi R, et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10:1758835918780140.
Zafar A, Drobni ZD, Mosarla R, et al. The incidence, risk factors, and outcomes with 5-fluorouracil-associated coronary vasospasm. JACC Cardio Oncol. 2021;3:101–9.
Zhou T, Zeng SX, Ye DW, et al. A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer. PLoS One. 2015;10:e0117002.
Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86:533–9.
Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016;34:2333–40.
Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33:4210–8.
Agarwal M, Thareja N, Benjamin M, Akhondi A, Mitchell GD. Tyrosine kinase inhibitor-induced hypertension. Curr Oncol Rep. 2018;20:65.
Waliany S, Sainani KL, Park LS, Zhang CA, Srinivas S, Witteles RM. Increase in blood pressure associated with tyrosine kinase inhibitors targeting vascular endothelial growth factor. JACC Cardio Oncol. 2019;1:24–36.
Budolfsen C, Faber J, Grimm D, et al. Tyrosine kinase inhibitor-induced hypertension: role of hypertension as a biomarker in cancer treatment. Curr Vasc Pharmacol. 2019;17:618–34.
Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–55.
Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol. 2018;37:2579–84.
Herrmann J, Yang EH, Iliescu CA, et al. Vascular toxicities of cancer therapies: the old and the new--an evolving avenue. Circulation. 2016;133:1272–89.
Drobni ZD, Alvi RM, Taron J, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142:2299–311.
Poels K, van Leent MMT, Boutros C, et al. Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis. JACC CardioOncol. 2020;2:599–610.
Acknowledgements
The figures were created using biorender.com
Author information
Authors and Affiliations
Contributions
All authors of this manuscript have significantly been involved in the conception and design or analysis and interpretation of the clinical information, drafting of the manuscript or revising it critically for important intellectual content.
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Prousi, G.S., Joshi, A.M., Atti, V. et al. Vascular Inflammation, Cancer, and Cardiovascular Diseases. Curr Oncol Rep 25, 955–963 (2023). https://doi.org/10.1007/s11912-023-01426-0
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11912-023-01426-0